Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Characteristics, Mutation Profiles and Outcomes of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease

Blood (2017) 130 (Supplement 1): 2670.

https://doi.org/10.1182/blood.V130.Suppl_1.2670.2670

Published: 2017

Journal Articles

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia Undergoing Remission Induction Therapy

Sudipto Mukherjee, MD, PhD, M.P.H., Paul Elson, PhD, Samjhana Bogati, BSN, Ashley Woltman, BSN, RN, John Desamito, Aaron T. Gerds, MD MS, Hetty E. Carraway, MD MBA, Anjali S. Advani, Yogen Saunthararajah, MD, Jaroslaw P Maciejewski, MD PhD FACP, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS

Blood (2016) 128 (22): 447.

https://doi.org/10.1182/blood.V128.22.447.447

Published: 2016

Journal Articles

Prognostic Impact of Molecular Mutations in AML at First Relapse

Anjali S. Advani, MD, Paul Elson, PhD, Valeria Visconte, PhD, Jennifer S. Carew, PhD, Jaime Fensterl, Bartlomiej Przychodzen, MSc, Mikkael A. Sekeres, MD MS, Cassandra M Hirsch, Alek Nielsen, John Desamito, Hetty E. Carraway, MD MBA, Aaron T. Gerds, MD MS, Betty K. Hamilton, MD, Sudipto Mukherjee, MD PhD, Ronald M. Sobecks, MD, Matt Kalaycio, MD, Yogen Saunthararajah, MD, Jaroslaw P. Maciejewski, MD PhD

Blood (2015) 126 (23): 3825.

https://doi.org/10.1182/blood.V126.23.3825.3825

Published: 2015

Journal Articles

Nitric Oxide As a Mediator of Bone Marrow Fibrosis in Patients with Myelofibrosis

Ali Tabarroki, MD, Daniel Lindner, MD PhD, Valeria Visconte, PhD, Nikolaos Papandantonakis, Jing Ai, MD PhD, Mikkael A. Sekeres, MD MS, Anjali S. Advani, MD, Matt E. Kalaycio, MD, Tracy Cinalli, RN, Kristin Colaluca, RN, Gina Rupp, John Desamito, Heesun J. Rogers, MD PhD, Ramon V. Tiu, MD

Blood (2014) 124 (21): 4587.

https://doi.org/10.1182/blood.V124.21.4587.4587

Published: 2014

Journal Articles

Modified Dose Escalation Of Ruxolitinib: A Feasible Therapeutic Approach In The Management Of Myelofibrosis

Ali Tabarroki, MD, Daniel Lindner, Valeria Visconte, PhD, Heesun J. Rogers, MD, PhD, John Desamito, Hien K. Duong, MD, Alan E. Lichtin, Anjali S. Advani, MD, Ronald M. Sobecks, MD, Tracy Cinalli, RN, Kristin Dodd, RN, Jing Ai, MD, PhD, Yogen Saunthararajah, M.D., Matt Kalaycio, MD, Brady L. Stein, MD, Mikkael A. Sekeres, MD, MS, Ramon V. Tiu, MD

Blood (2013) 122 (21): 1586.

https://doi.org/10.1182/blood.V122.21.1586.1586

Published: 2013

NARROW

Characteristics, Mutation Profiles and Outcomes of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia Undergoing Remission Induction Therapy

Prognostic Impact of Molecular Mutations in AML at First Relapse

Nitric Oxide As a Mediator of Bone Marrow Fibrosis in Patients with Myelofibrosis

Modified Dose Escalation Of Ruxolitinib: A Feasible Therapeutic Approach In The Management Of Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Characteristics, Mutation Profiles and Outcomes of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia Undergoing Remission Induction Therapy

Prognostic Impact of Molecular Mutations in AML at First Relapse

Nitric Oxide As a Mediator of Bone Marrow Fibrosis in Patients with Myelofibrosis

Modified Dose Escalation Of Ruxolitinib: A Feasible Therapeutic Approach In The Management Of Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only